단장증후군 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Short Bowel Syndrome Market size is expected to reach USD 4.00 Billion in 2034 from USD 1.92 Billion (2025) growing at a CAGR of 8.49% during 2026-2034.

The Global Short Bowel Syndrome Market is growing steadily due to the rising number of gastrointestinal surgeries and increasing cases of Crohn's disease and intestinal disorders. Short bowel syndrome (SBS) often requires long-term nutritional support, including parenteral nutrition and specialized drug therapies. Growing awareness among healthcare professionals and improved diagnosis are helping patients receive timely treatment. In addition, advancements in biologic therapies and intestinal rehabilitation programs are positively influencing market growth.

The main drivers of this market include increasing healthcare spending, a strong pipeline of targeted therapies, and supportive government policies for rare diseases. Pharmaceutical companies are investing in innovative drugs that improve nutrient absorption and reduce dependency on parenteral nutrition. Improved hospital infrastructure and access to specialized care centers are also supporting demand. Patient support programs and reimbursement policies in developed regions further boost treatment adoption.

In the future, the market is expected to benefit from advanced regenerative medicine and novel hormone-based treatments. Research in gut adaptation therapies and microbiome-based solutions may open new growth opportunities. Emerging economies are likely to see improved access to treatment as healthcare systems expand. Overall, continuous clinical research and patient-focused innovations will shape the long-term development of the Short Bowel Syndrome Market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• GLP-2
• Growth Hormone
• Glutamine

By Distribution Channel

• Hospital Pharmacies
• Online & Retail Pharmacies

COMPANIES PROFILED

• Takeda Pharmaceutical Company Limited, , OxThera, Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharm Co Ltd, Jaguar Health, Merck KGaA, EnteraBio Ltd, Nestl, Salix Pharmaceuticals
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SHORT BOWEL SYNDROME MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. GLP-2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Growth Hormone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Glutamine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SHORT BOWEL SYNDROME MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Online & Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SHORT BOWEL SYNDROME MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL SHORT BOWEL SYNDROME INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 OxThera
  • 8.2.2 Zealand Pharma
  • 8.2.3 Ironwood Pharmaceuticals
  • 8.2.4 Hanmi Pharm Co. Ltd
  • 8.2.5 Jaguar Health
  • 8.2.6 Merck KGaA
  • 8.2.7 EnteraBio Ltd
  • 8.2.8 NestlAfA(C)
  • 8.2.9 Salix Pharmaceuticals